Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine rich repeat containing 37 member A11, pseudogene (LRRC37A11P) is a non-protein-coding pseudogene that belongs to the leucine rich repeat-containing family, but does not encode a functional protein[1]. Pseudogenes like LRRC37A11P are typically regarded as genomic remnants derived from functional genes, but they can play regulatory roles at the RNA level, such as serving as microRNA decoys or influencing the stability of related mRNAs[4][5]. However, there is no evidence that LRRC37A11P encodes a therapeutic target, nor that it directly participates in canonical signaling, catalysis, or transport. There are no specific drugs, biomarkers, or disease pathways established for this pseudogene. Context and Supporting Details: - LRRC37A11P is not a receptor, enzyme, transporter, or transcription factor; it is a pseudogene, meaning it is a disabled copy of a gene that does not produce a functional protein[1]. - While some pseudogenes have emerging RNA-based regulatory roles (such as miRNA decoy or competitive endogenous RNA activity), there is no specific evidence for such a function for LRRC37A11P itself, and it is not listed as a disease-relevant or pharmacological target[4][5]. - GeneCards and other gene databases do not ascribe protein function, disease association, or druggability to LRRC37A11P[1]. Summary judgment: LRRC37A11P is a non-coding pseudogene not considered a druggable or canonical target. There are no therapeutic drugs or direct biological functions associated specifically with LRRC37A11P. Its broader family (pseudogenes) may have regulatory RNA functions, but such roles are not confirmed for this specific entry[4][5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine rich repeat containing 37 member A11, pseudogene (LRRC37A11P).